Evidence-informed pharmacology monograph. Reviewed 10 November 2026. Educational material only; clinical use requires current local product labeling and patient-specific assessment.
Overview and chemistry
Sumatriptan is an indole-derived selective serotonin 5-HT1B/1D receptor agonist (a triptan) used for acute migraine treatment and, in injectable form, selected cluster headache attacks. It is not a drug for migraine prophylaxis. The original article incorrectly described CYP2D6 as its principal metabolic route; sumatriptan is mainly metabolized by monoamine oxidase A (MAO-A) [1,2].
Mechanism of action
Sumatriptan stimulates 5-HT1B receptors on cranial blood vessels and 5-HT1D receptors associated with trigeminal nerve signaling, producing cranial vasoconstriction and reducing release of pain-related neuropeptides. Effects on the trigeminovascular system can abort migraine attacks. Clinical response and onset differ across oral, intranasal and subcutaneous products and must not be treated as dose-equivalent [1].
Indications and administration principles
Oral and nasal formulations treat migraine with or without aura in appropriately selected patients, whereas subcutaneous treatment can provide faster relief and is approved for some cluster headache indications. Sumatriptan works best when taken early in a recognized attack, but repeated or atypical headaches require diagnostic evaluation. It should not be used continuously or too frequently, because medication-overuse headache can result [1,2].
Cardiovascular and cerebrovascular contraindications
Current US labeling contraindicates sumatriptan in patients with coronary artery disease/coronary vasospasm, stroke/TIA, uncontrolled hypertension, peripheral vascular disease, ischemic bowel disease and certain accessory-pathway arrhythmias. Patients with multiple cardiovascular risk factors may need evaluation before starting therapy. Sudden severe or atypical headache requires assessment for secondary causes, including hemorrhage, before assuming migraine [2].
Drug interactions and serotonin toxicity
Sumatriptan must not be used with MAO-A inhibitors or within two weeks of their discontinuation; combining with other triptans or ergot medications within 24 hours is also contraindicated. Serotonin syndrome has been reported, particularly with serotonergic antidepressants, though absolute risk with some SSRI/SNRI combinations is low and requires individualized risk assessment rather than reflexive blanket avoidance. Watch for clonus, hyperreflexia, hyperthermia or marked agitation [1,2].
Adverse effects and special considerations
Transient tingling, flushing, heaviness or tightness in the chest/neck, dizziness and injection-site reactions can occur. While many chest sensations are nonischemic, persistent or high-risk symptoms need immediate evaluation. Rare serious harms include myocardial ischemia, arrhythmias, stroke and seizures. Severe hepatic impairment is contraindicated for oral tablets under US labeling; dose adjustment is needed with milder hepatic dysfunction depending on product [2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- DailyMed. Sumatriptan succinate tablets: US prescribing information, revised April 20, 2026. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf9fd9fe-095b-4478-bd2e-a5534af07761
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.